Aprinocarsen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Aprinocarsen
Accession Number
DB06451
Type
Small Molecule
Groups
Investigational
Description

Aprinocarsen is a specific antisense oligonucleotide inhibitor of protein kinase C-alpha.

Structure
Thumb
Synonyms
  • Aprinocarsen
  • PKC-alpha
External IDs
ISIS 3521 / ISIS-3521 / LY 900003 / LY-900003 / LY900003
Product Ingredients
IngredientUNIICASInChI Key
Aprinocarsen sodium1U68ZWZ6OX331257-53-5Not applicable
International/Other Brands
Affintak
Categories
UNII
FMT95051CQ
CAS number
151879-73-1
Weight
Average: 6435.16
Monoisotopic: 6430.594330658
Chemical Formula
C196H249N68O105P19S19
InChI Key
NMYKBZSMOUFOJV-UHFFFAOYSA-N
InChI
InChI=1S/C196H249N68O105P19S19/c1-75-37-249(189(285)237-165(75)267)132-23-89(109(337-132)51-313-371(294,390)351-84-18-141(331-103(84)45-265)259-69-215-149-159(259)225-179(203)231-173(149)275)359-378(301,397)320-54-112-92(26-135(340-112)252-40-78(4)168(270)240-192(252)288)358-377(300,396)315-48-106-86(20-129(334-106)246-14-10-124(198)222-186(246)282)353-372(295,391)318-52-110-90(24-133(338-110)250-38-76(2)166(268)238-190(250)286)356-376(299,395)316-49-107-88(22-131(335-107)248-16-12-126(200)224-188(248)284)355-374(297,393)326-60-118-98(32-142(346-118)260-70-216-150-160(260)226-180(204)232-174(150)276)365-383(306,402)317-50-108-87(21-130(336-108)247-15-11-125(199)223-187(247)283)354-373(296,392)319-53-111-95(29-138(339-111)255-43-81(7)171(273)243-195(255)291)362-381(304,400)328-62-120-102(36-146(348-120)264-74-220-154-164(264)230-184(208)236-178(154)280)369-388(311,407)330-64-122-100(34-144(350-122)262-72-218-152-162(262)228-182(206)234-176(152)278)367-385(308,404)324-58-116-96(30-139(344-116)256-44-82(8)172(274)244-196(256)292)363-382(305,401)327-61-119-101(35-145(347-119)263-73-219-153-163(263)229-183(207)235-177(153)279)368-387(310,406)325-59-117-97(31-140(345-117)258-68-214-148-156(202)210-66-212-158(148)258)364-386(309,405)329-63-121-99(33-143(349-121)261-71-217-151-161(261)227-181(205)233-175(151)277)366-384(307,403)323-57-115-94(28-137(343-115)254-42-80(6)170(272)242-194(254)290)361-380(303,399)322-56-114-93(27-136(342-114)253-41-79(5)169(271)241-193(253)289)360-379(302,398)321-55-113-91(25-134(341-113)251-39-77(3)167(269)239-191(251)287)357-375(298,394)314-47-105-85(19-128(333-105)245-13-9-123(197)221-185(245)281)352-370(293,389)312-46-104-83(266)17-127(332-104)257-67-213-147-155(201)209-65-211-157(147)257/h9-16,37-44,65-74,83-122,127-146,265-266H,17-36,45-64H2,1-8H3,(H,293,389)(H,294,390)(H,295,391)(H,296,392)(H,297,393)(H,298,394)(H,299,395)(H,300,396)(H,301,397)(H,302,398)(H,303,399)(H,304,400)(H,305,401)(H,306,402)(H,307,403)(H,308,404)(H,309,405)(H,310,406)(H,311,407)(H2,197,221,281)(H2,198,222,282)(H2,199,223,283)(H2,200,224,284)(H2,201,209,211)(H2,202,210,212)(H,237,267,285)(H,238,268,286)(H,239,269,287)(H,240,270,288)(H,241,271,289)(H,242,272,290)(H,243,273,291)(H,244,274,292)(H3,203,225,231,275)(H3,204,226,232,276)(H3,205,227,233,277)(H3,206,228,234,278)(H3,207,229,235,279)(H3,208,230,236,280)
IUPAC Name
1-[4-({[(3-{[({3-[({[3-({[(3-{[({3-[({[3-({[(3-{[({3-[({[3-({[(3-{[({3-[({[5-(6-amino-9H-purin-9-yl)-3-({[(3-{[({3-[({[3-({[(3-{[({3-[({[5-(6-amino-9H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy}(hydroxy)sulfanylidene-lambda5-phosphanyl)oxy]-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl}methoxy)(hydroxy)sulfanylidene-lambda5-phosphanyl]oxy}-5-(4-hydroxy-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)oxolan-2-yl)methoxy](hydroxy)sulfanylidene-lambda5-phosphanyl}oxy)-5-(4-hydroxy-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}(hydroxy)sulfanylidene-lambda5-phosphanyl)oxy]-5-(4-hydroxy-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)oxolan-2-yl}methoxy)(hydroxy)sulfanylidene-lambda5-phosphanyl]oxy}-5-(6-hydroxy-2-imino-3,9-dihydro-2H-purin-9-yl)oxolan-2-yl)methoxy](hydroxy)sulfanylidene-lambda5-phosphanyl}oxy)oxolan-2-yl]methoxy}(hydroxy)sulfanylidene-lambda5-phosphanyl)oxy]-5-(6-hydroxy-2-imino-3,9-dihydro-2H-purin-9-yl)oxolan-2-yl}methoxy)(hydroxy)sulfanylidene-lambda5-phosphanyl]oxy}-5-(4-hydroxy-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)oxolan-2-yl)methoxy](hydroxy)sulfanylidene-lambda5-phosphanyl}oxy)-5-(6-hydroxy-2-imino-3,9-dihydro-2H-purin-9-yl)oxolan-2-yl]methoxy}(hydroxy)sulfanylidene-lambda5-phosphanyl)oxy]-5-(6-hydroxy-2-imino-3,9-dihydro-2H-purin-9-yl)oxolan-2-yl}methoxy)(hydroxy)sulfanylidene-lambda5-phosphanyl]oxy}-5-(4-hydroxy-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)oxolan-2-yl)methoxy](hydroxy)sulfanylidene-lambda5-phosphanyl}oxy)-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}(hydroxy)sulfanylidene-lambda5-phosphanyl)oxy]-5-(6-hydroxy-2-imino-3,9-dihydro-2H-purin-9-yl)oxolan-2-yl}methoxy)(hydroxy)sulfanylidene-lambda5-phosphanyl]oxy}-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl)methoxy](hydroxy)sulfanylidene-lambda5-phosphanyl}oxy)-5-(4-hydroxy-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}(hydroxy)sulfanylidene-lambda5-phosphanyl)oxy]-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl}methoxy)(hydroxy)sulfanylidene-lambda5-phosphanyl]oxy}-5-(4-hydroxy-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)oxolan-2-yl)methoxy](hydroxy)sulfanylidene-lambda5-phosphanyl}oxy)-5-({[hydroxy({[5-(6-hydroxy-2-imino-3,9-dihydro-2H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy})sulfanylidene-lambda5-phosphanyl]oxy}methyl)oxolan-2-yl]-4-hydroxy-5-methyl-1,2-dihydropyrimidin-2-one
SMILES
[H]C1(O)CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])COP(O)(=S)OC1([H])CC([H])(OC1([H])CO)N1C=NC2=C1NC(=N)N=C2O)N1C=C(C)C(O)=NC1=O)N1C=C(C)C(O)=NC1=O)N1C=CC(=N)N=C1O)N1C=C(C)C(O)=NC1=O)N1C=CC(=N)N=C1O)N1C=NC2=C1NC(=N)N=C2O)N1C=CC(=N)N=C1O)N1C=C(C)C(O)=NC1=O)N1C=NC2=C1NC(=N)N=C2O)N1C=NC2=C1NC(=N)N=C2O)N1C=C(C)C(O)=NC1=O)N1C=NC2=C1NC(=N)N=C2O)N1C=NC2=C(N)N=CN=C12)N1C=NC2=C1NC(=N)N=C2O)N1C=C(C)C(O)=NC1=O)N1C=C(C)C(O)=NC1=O)N1C=C(C)C(O)=NC1=O)N1C=CC(=N)N=C1O)N1C=NC2=C(N)N=CN=C12

Pharmacology

Indication

Investigated for use/treatment in lung cancer.

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UProtein kinase C alpha typeNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Lung / Pulmonary Neoplasms1
2CompletedTreatmentLung Cancers / Melanoma (Skin)1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3CompletedTreatmentLung Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP12.87ChemAxon
pKa (Strongest Acidic)1.03ChemAxon
Physiological Charge-7ChemAxon
Hydrogen Acceptor Count119ChemAxon
Hydrogen Donor Count57ChemAxon
Polar Surface Area2279.07 Å2ChemAxon
Rotatable Bond Count116ChemAxon
Refractivity1555.79 m3·mol-1ChemAxon
Polarizability575.31 Å3ChemAxon
Number of Rings48ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differenti...
Gene Name
PRKCA
Uniprot ID
P17252
Uniprot Name
Protein kinase C alpha type
Molecular Weight
76749.445 Da
References
  1. Lahn M, Sundell K, Kohler G: The role of protein kinase C-alpha in hematologic malignancies. Acta Haematol. 2006;115(1-2):1-8. [PubMed:16424642]
  2. Vansteenkiste J, Canon JL, Riska H, Pirker R, Peterson P, John W, Mali P, Lahn M: Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer. Invest New Drugs. 2005 Jun;23(3):263-9. [PubMed:15868384]

Drug created on March 19, 2008 10:33 / Updated on June 04, 2019 06:24